Cardiovascular Disease Research

At Policum Berlin Studien GmbH investigators are exploring new treatments for heart‑related conditions, including heart failure with preserved or mildly reduced ejection fraction, obesity‑related cardiac risk, type‑2 diabetes, hypertension and broader cardiovascular disease. The studies aim to assess whether novel drug combinations can lower hospitalisations, improve survival and reduce disease progression.

  • Evaluation of a combined therapy with vicadrostat and empagliflozin for patients with diabetes, high blood pressure and established cardiovascular disease
  • Assessment of maridebart cafraglutide in reducing heart‑failure events among individuals with HFpEF or HFmrEF and elevated body‑mass index
  • Investigation of NNC0487-0111 as a weekly injection to decrease cardiovascular death and urgent heart‑failure visits in obese patients with HFpEF/HFmrEF
  • Comparison of cardiovascular outcomes in participants receiving standard care versus added investigational agents targeting heart‑failure pathways

These cardiovascular trials reflect the site’s commitment to advancing therapies that address the growing burden of heart disease in Europe.

Respiratory Disease Research

The Berlin centre conducts multiple studies on chronic lung disorders, focusing on asthma and chronic obstructive pulmonary disease (COPD). Researchers are testing inhaled medicines, biologic agents and novel delivery systems to improve lung function, lessen exacerbations and enhance quality of life for patients with varying disease severity.

  • Comparison of inhaler propellants for CHF5993 to determine therapeutic equivalence in mild to moderate asthma
  • Evaluation of BFF MDI versus standard inhalers for patients with inadequately controlled asthma
  • Assessment of triple inhaled therapy (BGF MDI) against dual bronchodilator treatment for severe cardiopulmonary outcomes in COPD
  • Study of tozorakimab as an add‑on therapy to reduce moderate to severe COPD exacerbations in former smokers
  • Investigation of depemokimab for type‑2 inflammation‑driven COPD and its impact on exacerbation rates

By targeting both asthma and COPD, the site contributes to the development of safer, more effective respiratory treatments for patients across Europe.